Literature DB >> 2684556

Lung defenses against opportunistic infections.

M F Lipscomb1.   

Abstract

This review has examined the possible role of CMI in providing protection against three pathogens that can be opportunists in the lung. Monoclonal antibodies that identify the cellular components of the immune response and recombinant cytokines are important tools to better understand how pulmonary immunity is regulated. Although not discussed in detail, recombinant microbial antigens are useful for understanding various aspects of protective immunity and immunosuppression as well as for advancing vaccine development. There are important problems to address in order to continue steady progress in understanding pulmonary defenses, including some of those mentioned in this brief review. There should be an increased use of infectious models that more closely mimic naturally occurring infections, and comparisons should be made between results obtained with parenteral versus intrapulmonary routes of infection.

Entities:  

Mesh:

Year:  1989        PMID: 2684556     DOI: 10.1378/chest.96.6.1393

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat.

Authors:  D Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

2.  Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung.

Authors:  H A Jaffe; R Buhl; A Mastrangeli; K J Holroyd; C Saltini; D Czerski; H S Jaffe; S Kramer; S Sherwin; R G Crystal
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice.

Authors:  G B Huffnagle; J L Yates; M F Lipscomb
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

Review 4.  The regulation of pulmonary immunity.

Authors:  M F Lipscomb; D E Bice; C R Lyons; M R Schuyler; D Wilkes
Journal:  Adv Immunol       Date:  1995       Impact factor: 3.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.